Tenecteplase versus alteplase for thrombolysis in patients selected by use of perfusion imaging within 4·5 h of onset of ischaemic stroke (TASTE): a multicentre, randomised, controlled, phase 3 non-inferiority trial

Mark Parsons(UNSW Sydney), Andrew Bivard(Hunter Medical Research Institute), Chon‐Haw Tsai(MACOM (United States)), Jiunn‐Tay Lee(Tri-Service General Hospital), Chushuang Chen(Liverpool Hospital), Vignan Yogendrakumar(Ottawa Hospital), Leonid Churilov(The University of Melbourne), Christopher Levi(John Hunter Hospital), John Fink(Christchurch Hospital), Brian Buck(University of Alberta), Tissa Wijeratne(Sunshine Hospital), Timothy Kleinig(Royal Adelaide Hospital), Daniel Strbian(Helsinki University Hospital), Geoffrey A. Donnan(The Royal Melbourne Hospital), Thanh G. Phan(Monash Health), Jiann‐Shing Jeng(National Taiwan University Hospital), Stephen M. Davis(The Royal Melbourne Hospital), Akshay Deepak(National Institute of Technology Patna), Michael J. Devlin(Princess Alexandra Hospital), Philip Choi, Ferdinand Miteff, Carlos García-Esperón, Smriti Agarwal(Addenbrooke's Hospital), Felix Ng(Capital Medical University), Neil J. Spratt, Arman Sabet(Griffith University), Atte Meretoja(University of Helsinki), Bruce Campbell(The Royal Melbourne Hospital), Kenneth Butcher(University of Alberta), Juan F. Arenillas(Universidad de Valladolid), Dennis Cordato(Liverpool Hospital), Teddy Y. Wu(Christchurch Hospital), Gagan Sharma(The Royal Melbourne Hospital), Carlos A. Molina(Hebron University), Michelle Russell, Beng Lim Chew(Hunter New England Local Health District), Henry Ma(Monash Health), Hugh S Markus(University of Cambridge), Helen Brown(Princess Alexandra Hospital), Billy O'Brien(Gosford Hospital), Sunil K Munshi(Nottingham University Hospitals NHS Trust), Rohan Grimley(MACOM (United States)), Longting Lin(Liverpool Hospital)
The Lancet Neurology
June 13, 2024
Cited by 89


Related Papers